Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	338.34	242.08	399.27	276.47	869.19	397.66
Short-Term Investments	1,905	2,061	1,938	1,721	1,264	1,501
Cash & Short-Term Investments	2,243	2,303	2,338	1,997	2,133	1,899
Cash Growth	-9.94%	-1.48%	17.03%	-6.37%	12.32%	-24.30%
Receivables	24.61	92.19	97.78	25.54	61.9	76.2
Inventory	10.47	12.51	7.44	22.03	24.81	21.97
Other Current Assets	240.49	212.67	199.13	157.72	125.17	133.42
Total Current Assets	2,519	2,620	2,642	2,203	2,345	2,131
Property, Plant & Equipment	348.11	256.11	242.94	255.84	196.04	181.08
Long-Term Investments	52.21	41.02	42.99	40.37	32.32	15.06
Other Intangible Assets	-	-	-	-	-	27.94
Other Long-Term Assets	113.78	86.26	62.29	34.97	38.28	34.97
Total Assets	3,033	3,004	2,990	2,534	2,612	2,390
Accounts Payable	14.33	42.96	26.03	17.92	11.9	17.2
Accrued Expenses	156.33	178.05	215.62	189.28	127.37	155.89
Current Portion of Long-Term Debt	655.71	0.22	45.07	0.32	0.9	316.11
Current Portion of Leases	-	9.06	8.09	7.22	2.63	-
Current Income Taxes Payable	0.1	0.03	2.15	6.25	0.04	1.32
Current Unearned Revenue	76.99	78.99	151.13	90.58	97.71	108.38
Total Current Liabilities	903.46	309.32	448.09	311.56	240.55	598.9
Long-Term Debt	1,141	1,788	1,743	1,183	1,228	623.53
Long-Term Leases	262.67	161.81	170.88	178.94	19.43	-
Long-Term Unearned Revenue	107.91	156.5	241.18	287.77	351.88	424.05
Total Liabilities	2,415	2,415	2,603	1,961	1,840	1,646
Common Stock	0.16	0.16	0.14	0.14	0.14	0.14
Additional Paid-In Capital	3,046	2,869	2,215	2,060	1,964	1,896
Retained Earnings	-2,402	-2,250	-1,796	-1,430	-1,160	-1,131
Comprehensive Income & Other	-25.98	-30.81	-32.65	-57.48	-32.67	-21.07
Total Common Equity	617.97	588.35	386.69	572.89	771.74	743.28
Shareholders' Equity	617.97	588.35	386.69	572.89	771.74	743.28
Total Liabilities & Equity	3,033	3,004	2,990	2,534	2,612	2,390
Total Debt	2,059	1,959	1,967	1,369	1,251	939.64
Net Cash (Debt)	183.95	344.14	370.23	628.21	882.13	959.48
Net Cash Growth	-62.93%	-7.05%	-41.07%	-28.78%	-8.06%	-44.26%
Net Cash Per Share	1.16	2.30	2.59	4.43	6.26	6.87
Filing Date Shares Outstanding	161.97	158.96	145.75	142.95	141.69	140.86
Total Common Shares Outstanding	161.14	157.91	144.34	142.06	141.21	140.37
Working Capital	1,616	2,311	2,194	1,891	2,104	1,532
Book Value Per Share	3.84	3.73	2.68	4.03	5.47	5.30
Tangible Book Value	617.97	588.35	386.69	572.89	771.74	715.35
Tangible Book Value Per Share	3.84	3.73	2.68	4.03	5.47	5.10
Land	-	8.57	8.57	8.57	23.06	23.06
Buildings	-	41.23	41.23	41.16	144.05	137.88
Machinery	-	9.86	9.84	9.58	10.59	12.87
Leasehold Improvements	-	54.38	28.28	28.36	20.14	17.26

Updated Oct 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q